Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,721 to 4,740 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| EHR-based Alert vs Usual Care: Percentage of Patients on ARBs | 111 of 685 85 of 625 | 2.6 points -1.3 to 6.4 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients on Beta Blockers | 606 of 685 521 of 625 | 5.1 points 1.3 to 8.9 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | 176 of 685 117 of 625 | 7.0 points 2.5 to 11.4 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients on MRAs | 232 of 685 203 of 625 | 1.4 points -3.7 to 6.5 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients on ARNIs | 334 of 685 285 of 625 | 3.2 points -2.2 to 8.5 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients on ACE Inhibitors | 83 of 685 92 of 625 | -2.6 points -6.3 to 1.1 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Rate of One-year All-cause Mortality | 75 of 685 68 of 625 | 0.1 points -3.4 to 3.4 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Percentage of Patients on SGLT2 Inhibitors | 144 of 685 103 of 625 | 4.5 points 0.3 to 8.7 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: deaths from any cause | 75 of 685 68 of 625 | 0.1 points -3.4 to 3.4 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Rate of 30-day All-cause Emergency Department Visits | 86 of 685 77 of 625 | 0.2 points -3.4 to 3.8 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| EHR-based Alert vs Usual Care: Rate of 30-day Hospital Admission | 47 of 685 63 of 625 | -3.2 points -6.3 to -0.2 | 1,310 | NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure |
| CHG Cloth vs Placebo Cloth: Number of Participants With Incisional SSI | 17 of 662 24 of 647 | -1.1 points -3.1 to 0.8 | 1,309 | NCT02402907 STRIPES Study: Study To Reduce Infection Post cEsarean Section |
| CHG Cloth vs Placebo Cloth: Number of Participants With Endometritis | 0 of 662 1 of 647 | -0.2 points -0.9 to 0.4 | 1,309 | NCT02402907 STRIPES Study: Study To Reduce Infection Post cEsarean Section |
| Regional Anesthesia vs General Anesthesia: Satisfaction With Care | 85 of 647 97 of 661 | -1.5 points -5.3 to 2.2 | 1,308 | NCT02507505 Regional Versus General Anesthesia for Promoting Independence After Hip Fracture |
| RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose) vs Placebo Matching RotaTeq™: serious adverse events | 21 of 649 28 of 658 | -1.0 points -3.2 to 1.1 | 1,307 | NCT00092443 Dose Confirmation Efficacy Study (V260-007) |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: deaths from any cause | 107 of 652 77 of 655 | 4.7 points 0.9 to 8.4 | 1,307 | NCT00805194 LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 224 of 652 206 of 655 | 2.9 points -2.2 to 8.0 | 1,307 | NCT00805194 LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer |
| Treatment Period 2: Group 1 vs Treatment Period 2: Group 2: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 | 552 of 644 496 of 662 | 10.8 points 6.5 to 15.0 | 1,306 | NCT02409667 Plaque Psoriasis Efficacy and Safety With Secukinumab |
| SB204 4% vs Vehicle Gel: deaths from any cause | 0 of 654 1 of 652 | -0.2 points -0.9 to 0.4 | 1,306 | NCT02672332 P3 Study in Acne Comparing Once Daily SB204 and Vehicle |
| SB204 4% vs Vehicle Gel: serious adverse events | 0 of 654 4 of 652 | -0.6 points -1.6 to 0.1 | 1,306 | NCT02672332 P3 Study in Acne Comparing Once Daily SB204 and Vehicle |
Code
curl "https://conductscience.org/api/comparisons/v1?page=237"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=237
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04514458-0f250ec9",
"title": "EHR-based Alert vs Usual Care: Percentage of Patients on ARBs",
"summary": "111 of 685 against 85 of 625; risk difference 2.6 points, 95% interval -1.3 to 6.4; NCT04514458, Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure",
"record": "/library/comparisons/NCT04514458-0f250ec9",
"nct_id": "NCT04514458",
"kind": "outcome",
"participants": 1310,
"risk_difference": {
"value": 0.02604379562043796,
"lower": -0.012784357833962319,
"upper": 0.06446831747631585
},
"group_1": "111 of 685",
"group_2": "85 of 625",
"difference": "2.6 points",
"interval": "-1.3 to 6.4",
"trial_title": "Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure"
},
{
"id": "NCT04514458-166652b4",
"title": "EHR-based Alert vs Usual Care: Percentage of Patients on Beta Blockers",
"summary": "606 of 685 against 521 of 625; risk difference 5.1 points, 95% interval 1.3 to 8.9; NCT04514458, Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure",
"record": "/library/comparisons/NCT04514458-166652b4",
"nct_id": "NCT04514458",
"kind": "outcome",
"participants": 1310,
"risk_difference": {
"value": 0.051071532846715284,
"lower": 0.013419667922568282,
"upper": 0.089150727517845
},
"group_1": "606 of 685",
"group_2": "521 of 625",
"difference": "5.1 points",
"interval": "1.3 to 8.9",
"trial_title": "Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=238",
"request_id": "a0OjrcUZuli-coPm"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant